货号:A137025
同义名:
3-甲氧基-4-羟基苯基丙烯酸
/ Coniferic acid; 4-hydroxy-3-Methoxycinnamic Acid
Ferulic Acid是一种天然存在的酚类植物化学物,存在于植物细胞壁中,具有抗氧化作用。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | FGFR ↓ ↑ | FGFR1 ↓ ↑ | FGFR2 ↓ ↑ | FGFR3 ↓ ↑ | FGFR4 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyrphostin AG1296 |
+
FGFR (Swiss 3T3), IC50: 12.3 μM |
PDGFR | 99%+ | ||||||||||||||||
| Pazopanib |
+
FGFR, IC50: 140 nM |
99% | |||||||||||||||||
| Erdafitinib | ✔ | RET | 99%+ | ||||||||||||||||
| Gambogenic acid | ✔ | 98+% | |||||||||||||||||
| Sulfatinib |
+++
FGFR1, IC50: 15 nM |
99+% | |||||||||||||||||
| Nintedanib esylate |
+
FGFR1, IC50: 69 nM |
++
FGFR2, IC50: 37 nM |
+
FGFR3, IC50: 108 nM |
98% | |||||||||||||||
| Zoligratinib |
+++
FGFR1, IC50: 9.3 nM |
+++
FGFR2, IC50: 7.6 nM |
++
FGFR3, IC50: 22 nM |
+
FGFR4, IC50: 290 nM |
99%+ | ||||||||||||||
| MK-2461 |
+
FGFR1, IC50: 65 nM |
++
FGFR2, IC50: 39 nM |
++
FGFR3, IC50: 50 nM |
98%+ | |||||||||||||||
| SU 5402 |
++
FGFR1, IC50: 30 nM |
98% | |||||||||||||||||
| Brivanib |
+
FGFR1, IC50: 148 nM |
99%+ | |||||||||||||||||
| Lucitanib |
++
FGFR1, IC50: 17.5 nM |
+
FGFR2, IC50: 82.5 nM |
99%+ | ||||||||||||||||
| Ponatinib |
++++
FGFR1, IC50: 2.2 nM |
98% | |||||||||||||||||
| PD-166866 |
+
FGFR1, IC50: 52.4 nM |
99% | |||||||||||||||||
| Narazaciclib |
++
FGFR1, IC50: 26 nM |
RET | 99%+ | ||||||||||||||||
| Lactate |
+++
FGFR1, IC50: 8 nM |
+++
FGFR3, IC50: 9 nM |
c-Kit,FLT3 | 85% | |||||||||||||||
| Lenvatinib mesylate |
++
FGFR1, IC50: 46 nM |
c-RET | 99% | ||||||||||||||||
| LY2874455 |
++++
FGFR1, IC50: 2.8 nM |
++++
FGFR2, IC50: 2.6 nM |
+++
FGFR3, IC50: 6.4 nM |
+++
FGFR4, IC50: 6 nM |
99%+ | ||||||||||||||
| FIIN-2 |
+++
FGFR1, IC50: 3.09 nM |
+++
FGFR2, IC50: 4.3 nM |
++
FGFR3, IC50: 27 nM |
++
FGFR4, IC50: 45.3 nM |
99% | ||||||||||||||
| FIIN-3 |
+++
FGFR1, IC50: 13.1 nM |
++
FGFR2, IC50: 21 nM |
++
FGFR3, IC50: 31.4 nM |
++
FGFR4, IC50: 35.3 nM |
98% | ||||||||||||||
| Infigratinib |
++++
FGFR1, IC50: 0.9 nM |
++++
FGFR2, IC50: 1.4 nM |
++++
FGFR3 (K650E), IC50: 4.9 nM FGFR3, IC50: 1.0 nM |
+
FGFR4, IC50: 60 nM |
99%+ | ||||||||||||||
| Danusertib |
++
FGFR1, IC50: 47 nM |
RET | 99%+ | ||||||||||||||||
| R1530 |
++
FGFR1, IC50: 28 nM |
98% | |||||||||||||||||
| ENMD-2076 |
+
FGFR1, IC50: 92.7 nM |
+
FGFR2, IC50: 70.8 nM |
RET,FLT3 | 98% | |||||||||||||||
| Dovitinib |
+++
FGFR1, IC50: 8 nM |
+++
FGFR3, IC50: 9 nM |
c-Kit,FLT3 | 99%+ | |||||||||||||||
| Sorafenib |
+
FGFR1, IC50: 580 nM |
99% | |||||||||||||||||
| SSR128129E |
+
FGFR1, IC50: 1.9 μM |
99%+ | |||||||||||||||||
| AZD-4547 |
++++
FGFR1, IC50: 0.2 nM |
++++
FGFR2, IC50: 2.5 nM |
++++
FGFR3, IC50: 1.8 nM |
98% | |||||||||||||||
| Lenvatinib |
++
FGFR1, IC50: 46 nM |
RET | 98% | ||||||||||||||||
| PD173074 |
++
FGFR1, IC50: ~25 nM |
99%+ | |||||||||||||||||
| S49076 |
++
FGFR1, IC50: 18 nM |
+++
FGFR2, IC50: 17 nM |
+++
FGFR3, IC50: 15 nM |
98% | |||||||||||||||
| Futibatinib |
++++
FGFR1, IC50: 1.8 nM |
++++
FGFR2, IC50: 1.4 nM |
++++
FGFR3, IC50: 1.6 nM |
+++
FGFR4, IC50: 3.7 nM |
99%+ | ||||||||||||||
| Ferulic Acid |
+
FGFR1, IC50: 3.78 μM |
+
FGFR2, IC50: 12.5 μM |
98% | ||||||||||||||||
| Nintedanib |
+
FGFR1, IC50: 69 nM |
++
FGFR2, IC50: 37 nM |
+
FGFR3, IC50: 108 nM |
+
FGFR4, IC50: 610 nM |
99+% | ||||||||||||||
| ASP5878 |
++++
FGFR1, IC50: 0.47 nM |
++++
FGFR2, IC50: 0.6 nM |
++++
FGFR3, IC50: 0.74 nM |
+++
FGFR4, IC50: 3.5 nM |
99% | ||||||||||||||
| PRN1371 |
++++
FGFR1, IC50: 0.6 nM |
++++
FGFR2, IC50: 1.3 nM |
+++
FGFR3, IC50: 4.1 nM |
++
FGFR4, IC50: 19.3 nM |
99% | ||||||||||||||
| Derazantinib |
+++
FGFR1, IC50: 4.5 nM |
++++
FGFR2, IC50: 1.8 nM |
+++
FGFR3, IC50: 4.5 nM |
++
FGFR4, IC50: 34 nM |
RET | 99%+ | |||||||||||||
| ODM-203 |
+++
FGFR1, IC50: 11 nM |
+++
FGFR2, IC50: 16 nM |
+++
FGFR3, IC50: 6 nM |
++
FGFR4, IC50: 35 nM |
99%+ | ||||||||||||||
| Pemigatinib |
++++
FGFR1, IC50: 0.4 nM |
++++
FGFR2, IC50: 0.5 nM |
++++
FGFR3, IC50: 1.2 nM |
++
FGFR4, IC50: 30 nM |
99%+ | ||||||||||||||
| SKLB 610 | ✔ | PDGFR | 99%+ | ||||||||||||||||
| Alofanib | ✔ | 99%+ | |||||||||||||||||
| Lirafugratinib | ✔ | 99% | |||||||||||||||||
| Masitinib mesylate | ✔ | FAK | 99%+ | ||||||||||||||||
| BLU9931 |
+
FGFR3, IC50: 150 nM |
+++
FGFR4, IC50: 3 nM |
99%+ | ||||||||||||||||
| BO-264 | ✔ | 99%+ | |||||||||||||||||
| Fisogatinib |
+++
FGFR4, IC50: 5 nM |
99%+ | |||||||||||||||||
| H3B-6527 |
++++
FGFR4, IC50: <1.2 nM |
99%+ | |||||||||||||||||
| Roblitinib |
++++
FGFR4, IC50: 1.9 nM |
99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Ferulic Acid, a kind of phenolic compound isolated from Tetragonia tetragonioides, has many biological activities. In vitro studies, ferulic acid has whitening effect on the B16F10 mouse melanoma cell line and anti-wrinkle activity on the CCD-986sk human dermal fibroblast cell line, while shows no cytotoxicity at concentrations up to 20 μM[1]. Besides this, it was found that ferulic acid could effectively inhibit the epidermal growth factor receptor (EGFR) in human breast cancer cells, through down-regulating the Tyr 1068 autophosphorylation[2]. In vivo studies, ferulic acid has the ability of ameliorating the diabetes-induced cognition lesions in rat via the regulation of protein tyrosine phosphatase 1B (PTP1B) and insulin signaling pathway[3]. In addition, ferulic acid could contribute to the reversal of inflammatory response induced by chronic unpredictable mild stress (CUMS) in mice[4]. |
| Concentration | Treated Time | Description | References | |
| J774A.1 cells | 12.5-100 µg/ml | 2 h | To investigate the inhibitory effect of ferulic acid on NLRP3 inflammasome-mediated canonical pyroptosis, results showed that ferulic acid significantly inhibited the release of LDH and IL-1β | MedComm (2020). 2023 Apr 20;4(3):e255. |
| RAW264.7 cells | 50 µg/ml | 2 h | To investigate the inhibitory effect of ferulic acid on caspase-11 inflammasome-mediated non-canonical pyroptosis, results showed that ferulic acid significantly reduced LDH release and PI uptake | MedComm (2020). 2023 Apr 20;4(3):e255. |
| BMDMs | 50 µg/ml | 2 h | To investigate the inhibitory effect of ferulic acid on caspase-11 inflammasome-mediated non-canonical pyroptosis, results showed that ferulic acid significantly reduced LDH release and IL-1β secretion | MedComm (2020). 2023 Apr 20;4(3):e255. |
| Caco-2 cells | 0-500 µM | 24 h | To assess the dose-dependent toxicity of FA in vitro, cell viabilities were determined on Caco-2 using a WST assay. Up to 500 µM FA, cell survival was 100% for 24 h, while 1250 µM FA significantly reduced cell viability. | Antioxidants (Basel). 2022 Jul 26;11(8):1448. |
| Hippocampal Neurons | 5 and 10 µM | 2 h | FA preincubation prevented the Aβ-induced loss of synaptic proteins, including GluN2B, PSD-95, and synapsin1 | Neurotherapeutics. 2023 Jul;20(4):1081-1108. |
| BV2 microglial cells | 0.5 mg/ml | 18 h | To evaluate the regulatory effect of Ferulic Acid on BV2 microglial cell polarization under hypoxia, the results showed that Ferulic Acid significantly reduced the number of iNOS+ cells and increased the number of Arg1+ cells, indicating that Ferulic Acid can shift microglial polarization from M1 to M2 phenotype. | Front Immunol. 2022 Sep 2;13:976729. |
| Human retinal endothelial cells (HRECs) | 0.5 mg/ml | 16 h | To evaluate the effect of Ferulic Acid-treated microglial supernatants on HRECs tube formation and migration, the results showed that Ferulic Acid-treated microglial supernatants significantly inhibited HRECs tube formation and migration. | Front Immunol. 2022 Sep 2;13:976729. |
| Skeletal Stem Cells (SSCs) | 30 μM | 24 h | Ferulic acid significantly rescued the radiation-induced impairment of SSCs by restoring their proliferation, osteogenic differentiation, and self-renewal capacity, and by activating the p38/MAPK and ERK/MAPK pathways. | Stem Cells Transl Med. 2021 Aug;10(8):1217-1231. |
| Mouse tracheal epithelial cells (MTECs) | 0, 25, 50, 100, 200, 400, 800 μM | 24 h | To evaluate the effect of Ferulic Acid on the viability of MTECs, results showed that 25-200 μM Ferulic Acid significantly increased cell viability, while 400-800 μM began to show toxic effects. | Respir Res. 2021 Dec 4;22(1):308. |
| Mouse tracheal epithelial cells (MTECs) | 200 μM | 24 h | To evaluate the effect of Ferulic Acid on ENaC activity in LPS-induced MTECs, results showed that Ferulic Acid reversed the LPS-induced reduction of ENaC activity. | Respir Res. 2021 Dec 4;22(1):308. |
| Administration | Dosage | Frequency | Description | References | ||
| Rats | Insomnia model | Oral | 40 mg/kg | Single dose | The pharmacokinetics and tissue distribution of FA-SMEDDS were evaluated. The results showed that FA-SMEDDS significantly improved the oral bioavailability of FA, reduced its distribution in the kidney, and increased its distribution in the brain. | Int J Nanomedicine. 2020 Mar 25;15:2059-2070 |
| C57BL/6 mice | LPS-induced sepsis model | Intraperitoneal injection | 50 mg/kg | Single injection, lasting 6 hours | To investigate the protective effect of ferulic acid on LPS-induced septic mice, results showed that ferulic acid significantly improved the survival rate and reduced the serum concentrations of IL-1β and TNF-α | MedComm (2020). 2023 Apr 20;4(3):e255. |
| Mice | High-fat diet model | Dietary supplementation | 50 mg/kg | 8 weeks | To investigate the effect of FA on gut health in mice fed a high-fat diet, results showed that FA reduced lymphocyte infiltration and protected the intestinal epithelial barrier. | Antioxidants (Basel). 2022 Jul 26;11(8):1448. |
| APP/PS1 mice | Alzheimer's disease model | Drinking water | 20 mg/kg | Once daily for 30 days | Ferulic acid counteracts ET1-mediated vasoconstriction, prevents reductions in density and diameter of hippocampal capillaries, and ameliorates Aβ plaque deposition and spatial memory deficits | Neurotherapeutics. 2021 Apr;18(2):1064-1080 |
| APP/PS1 Mice | Alzheimer's Disease Model | Oral | 50 mg/kg | Once daily for 4 months | Long-term FA treatment improved behavioral and cognitive functions, reduced Aβ burden, and improved synaptic plasticity in APP/PS1 mice | Neurotherapeutics. 2023 Jul;20(4):1081-1108. |
| C57BL/6J mice | Oxygen-induced retinopathy (OIR) model | Intragastric administration | 50 mg/kg | Twice daily for 5 days (P12 to P17) | To evaluate the inhibitory effect of Ferulic Acid on retinal neovascularization in the OIR model, the results showed that Ferulic Acid significantly reduced the area of retinal neovascular clusters and the number of endothelial cells, and promoted reparative angiogenesis. | Front Immunol. 2022 Sep 2;13:976729. |
| C57BL/J male mice | LPS-induced tracheal injury model | Intraperitoneally | 100 mg/kg | 12 hours before and 12 hours after intratracheal administration of LPS | To evaluate the protective effect of Ferulic Acid on LPS-induced tracheal injury, results showed that Ferulic Acid significantly attenuated tracheal injury and restored the structure of tracheal epithelial cells and ENaC expression. | Respir Res. 2021 Dec 4;22(1):308. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03092076 | Healthy | Phase 1 | Completed | - | - |
| NCT01982734 | Pharmacokinetics of New Curcum... 展开 >>in Formulations Safety of New Curcumin Formulations 收起 << | Early Phase 1 | Completed | - | Germany ... 展开 >> University of Hohenheim Stuttgart, Baden-Württemberg, Germany, 70599 收起 << |
| NCT02944084 | Safety After Oral Intake ... 展开 >> Pharmacokinetics After Oral Intake 收起 << | Early Phase 1 | Completed | - | Germany ... 展开 >> University of Hohenheim Stuttgart, Baden-Württemberg, Germany, 70599 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
5.15mL 1.03mL 0.52mL |
25.75mL 5.15mL 2.57mL |
51.50mL 10.30mL 5.15mL |
|
| CAS号 | 1135-24-6 |
| 分子式 | C10H10O4 |
| 分子量 | 194.18 |
| SMILES Code | C1=C(C=CC(O)=O)C=CC(=C1OC)O |
| MDL No. | MFCD00004400 |
| 别名 | 3-甲氧基-4-羟基苯基丙烯酸 ;Coniferic acid; 4-hydroxy-3-Methoxycinnamic Acid; Ferulic Acid, Methyl ferulate, trans-Ferulic acid, Coniferic acid, NSC 2821, NSC2821, NSC-2821; NSC 674320; NSC 51986; NSC 2821; Fumalic Acid |
| 运输 | 蓝冰 |
| InChI Key | KSEBMYQBYZTDHS-HWKANZROSA-N |
| Pubchem ID | 445858 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(540.72 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1